BMJ Open Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study

Yi-Hao Peng,^{1,2,3} Chien-Wen Huang,^{4,5,6} Wei-Chih Liao,^{7,8} Hsuan-Ju Chen,^{8,9} Ming-Chien Yin,^{1,10} Yu-Ming Huang,² Trong-Neng Wu,¹¹ Wen-Chao Ho¹

To cite: Peng Y-H, Huang C-W, Liao W-C, *et al.* Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study. *BMJ Open* 2017;7:e015581. doi:10.1136/bmjopen-2016-015581

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-015581>).

Received 16 December 2016
Revised 14 April 2017
Accepted 23 May 2017

ABSTRACT

Objective Chronic obstructive pulmonary disease (COPD) and benign prostatic hyperplasia (BPH) are common disorders in ageing male populations. Nevertheless, the relationship between the two diseases has rarely been explored. The objective of this study was to examine whether patients with COPD are at an increased risk of BPH.

Design Retrospective nationwide cohort study.

Setting Data retrieved from the Taiwan National Health Insurance Research Database.

Participants Overall, 19 959 male patients aged 40 years and over with newly diagnosed COPD between 2000 and 2006 were included as the COPD group, and 19 959 sex-matched and age-matched enrollees without COPD were included as the non-COPD group. Both groups were followed-up until the end of 2011.

Outcome measures A Cox proportional hazards regression model was used to compute the risk of BPH in patients with COPD compared with enrollees without COPD.

Results The overall incidence rate of BPH was 1.53 times higher in the COPD group than that in the non-COPD group (44.7 vs 25.7 per 1000 person-years, 95% CI 1.46 to 1.60) after adjusting for covariates. An additional stratified analysis revealed that this increased risk of BPH in patients with COPD remained significantly higher than that in enrollees without COPD in all men aged 40 years and over.

Conclusion After adjustment for covariates, male patients with COPD were found to be at a higher risk of BPH. We suggest that clinicians should be cautious about the increased risk of BPH in male patients with COPD.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD), predominantly prevalent in men, is a chronic inflammatory disorder of the airway and lungs. COPD is one of the most prevalent diseases and the third leading cause of death globally.¹ Patients with COPD usually present with progressive dyspnoea, shortness of breath and productive cough. Moreover, they frequently experience various comorbid

Strengths and limitations of this study

- This is the first large cohort study to demonstrate that male patients with chronic obstructive pulmonary disease were at a higher risk of benign prostatic hyperplasia.
- The data we used were retrieved from the Taiwan National Health Insurance Research Database, which is highly representative of the general population.
- Detailed patients information, as well as information regarding clinical variables were lacking. Unknown confounding factors might remain, leading to bias in the study results.

conditions, such as cardiovascular disease, metabolic disorder, dementia and skeletal muscle dysfunction.^{2–3} These comorbidities might have a significant effect on patient outcome.⁴ COPD is currently recognised as a chronic systemic inflammatory state because the inflammation involves the lung and may contribute to various extrapulmonary effects.^{5,6}

Benign prostatic hyperplasia (BPH) is a common medical condition in older male populations. Approximately 14% of men aged 40–49 years are estimated to have BPH, and the prevalence increases to >50% in men aged 60 years and over.^{7,8} Patients with BPH usually present with lower urinary tract symptoms (LUTS), such as urinary urgency and retention, considerably affecting the quality of their lives. In addition to ageing, other reported predisposing factors for BPH are metabolic syndrome, obesity and reduced physical activity.^{9–11}

Although COPD and BPH are associated with chronic inflammation of the airway and prostate, respectively,^{12,13} and are common disorders in ageing male populations, the relationship between these two conditions has rarely been explored. In addition, previous

CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Wen-Chao Ho;
whocmu@gmail.com

studies have suggested that COPD and BPH might share an underlying pathophysiology. For example, higher levels of interleukin (IL-6) and C reactive protein (CRP) in serum or sputum were observed in both patients with COPD and BPH.^{14–16} Moreover, while patients with COPD appear to be more physically inactive than their counterpart without COPD,¹⁷ studies have suggested that level of physical activity was negatively associated with BPH risk. This implies that physical inactivity among patients with COPD might also be a contributing factor for BPH development.¹⁸ In the present study, we investigated whether the risk of BPH increased in patients with COPD by using a retrospective nationwide cohort study design and data retrieved from the Taiwan National Health Insurance Research Database (NHIRD).

METHODS

Data sources

The National Health Insurance (NHI) programme is a universal insurance programme established on 1 March 1995, which reformed 13 insurance-related systems to provide comprehensive medical care coverage for up to 99% of the inhabitants of Taiwan by the end of 2014. The current study was a population-based cohort study that used data between 1996 and 2011 from the NHIRD, which was established by the National Health Research Institutes (NHRI) with authorisation from the Bureau of National Health Insurance and the Department of Health. In the present study, we used datasets from the Registry for Longitudinal Health Insurance Database 2000 (LHID 2000), which contains medical reimbursement claims data of the NHI programme for 1 million individuals. The NHI reported no differences in the sex and age distributions between the data in the LHID 2000 and beneficiary data in the entire NHI database; thus, the LHID 2000 was considered representative of the general population. The LHID 2000 contains comprehensive information including demographic data, clinical visit dates, diagnostic codes and prescription details.¹⁹ For security and privacy purposes, patient identity data are encrypted by the NHIRD before releasing them for research purposes.

Study population

From 1 January 2000 to 31 December 2006, 25 036 male patients with COPD were identified from the NHIRD as the potential COPD study population. COPD was diagnosed using the *International Classification of Diseases*, Ninth Revision, Clinical Modification (ICD-9-CM) codes 491, 492 and 496. To ensure the accuracy of diagnosis, we defined patients as having COPD only when the diagnosis was confirmed at least thrice by outpatient services or inpatient hospitalisation claims. The date of COPD diagnosis was considered as the index date. We excluded patients with missing age or sex information (n=3), those younger than 40 years (n=4264) and those with a history of BPH before the index date (n=810) from the COPD

group. For each patient with COPD, one insured individual without COPD was randomly selected from the LHID 2000 to form the non-COPD group, and frequency-matched for sex, 5-year age interval and index year by considering the same inclusion criteria as that for the COPD group.

The demographic factors considered were age (age groups: 40–54, 55–69 and ≥70 years) and annual outpatient department (OPD) visits. Information regarding critical comorbidities of each individual was retrieved from the medical claims based on the ICD-9-CM codes. Comorbidities such as diabetes mellitus (DM, ICD-9-CM code 250), dyslipidemia (ICD-9-CM code 272), hypertension (ICD-9-CM codes 401–405), heart failure (ICD-9-CM code 428) and coronary artery disease (CAD, ICD-9-CM codes 410–414) were obtained before the index date. Patients were considered long-term users of tiotropium or ipratropium if they had been prescribed tiotropium or ipratropium during the follow-up period.

The primary outcome was BPH, which was determined by at least thrice diagnosis confirmations during inpatient hospitalisation or outpatient service, based on the ICD-9-CM diagnosis code 600.0. The follow-up began on the index date and lasted until the first diagnosis date of BPH, withdrawal from NHI or 31 December 2011, whichever occurred first.

Statistical analysis

Continuous data were summarised using mean and SD, and categorical variables were summarised using frequency and percentage. Continuous variables were compared using a Student's t-test, and the categorical variables were compared using a χ^2 test. The incidence rate (per 1000 person-years) of BPH was calculated by dividing the number of BPH cases by person-time at risk. The cumulative BPH incidence curve was plotted using the Kaplan-Meier method and statistical significance was examined using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to analyse the association between BPH-associated risk factors and the incidence of BPH. Age, DM, dyslipidemia, hypertension, heart failure, CAD, tiotropium use, ipratropium use and annual OPD visits were included as covariates in the multivariate Cox regression model. In addition, we performed age-stratified and comorbidity-stratified analyses to estimate the association between COPD and the risk of BPH. HRs and 95% CIs were calculated to quantify the risk of BPH. The analyses were conducted using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA), and significance was considered as a two-sided $p<0.05$.

RESULTS

In this study, 19 959 patients with COPD and 19 959 enrollees without COPD were enrolled (table 1). The mean ages of the COPD and non-COPD groups were 64.5 years (SD=12.2 years) and 63.8 years (SD=12.4 years),

Table 1 Comparisons of baseline demographic factors and comorbidities between study enrollees with and without COPD

Variable	Non-COPD group n=19959		COPD group n=19959		p Value
	n	%	n	%	
Age, years					>0.99
40–54	5141	25.8	5141	25.8	
55–69	7274	36.4	7274	36.4	
≥70	7544	37.8	7544	37.8	
Mean (SD)*	63.8	(12.4)	64.5	(12.2)	<0.001
Comorbidity					
DM	2595	13.0	3209	16.1	<0.001
Dyslipidemia	3267	16.4	4621	23.2	<0.001
Hypertension	7672	38.4	10 432	52.3	<0.001
Heart failure	375	1.88	981	4.92	<0.001
CAD	3141	15.7	5739	28.8	<0.001
Medication					
Use of tiotropium†	0	0.00	39	0.20	<0.001
Use of ipratropium†	2	0.01	135	0.68	<0.001
Annual OPD visits					<0.001
<30	16 050	80.4	10 869	54.5	
≥30	3909	19.6	9090	45.5	
Mean (SD)*	18.9	(17.1)	32.8	(22.4)	<0.001

*Student's t-test.

†Fisher's exact test.

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; OPD, outpatient department.

respectively. The COPD group had a higher prevalence of comorbidity (including DM, dyslipidemia, hypertension, heart failure and CAD) and medications (including tiotropium and ipratropium) than did the non-COPD group. The median annual OPD visits of the COPD and non-COPD groups were 32.8 (SD=22.4) and 18.9 (SD=17.1), respectively.

Cumulative incidence curves of BPH for the COPD and non-COPD groups are presented in figure 1. The cumulative incidence of BPH was significantly higher in the COPD group than that in the non-COPD group (log-rank test, $p<0.001$).

During a median follow-up of 6.93 (95% CI 6.88 to 6.98) years, 5690 patients were diagnosed as having BPH in the COPD group, and 3590 patients were diagnosed as having BPH in the non-COPD group, with an incidence rate of 44.7 and 25.7 per 1000 person-years, respectively. Cox proportional hazards regression analysis showed that patients with COPD had a greater risk of BPH than did enrollees without COPD after adjusting for age, comorbidities, medicine use and annual OPD visits (adjusted HR 1.53; 95% CI 1.46 to 1.60; table 2). The risk of BPH appears to increase with age. Individuals aged 55–69 years and those older than 70 years had adjusted HRs of 2.76 (95% CI 2.58 to 2.96) and 3.84 (95% CI 3.58 to 4.12), respectively, compared with individuals aged 40–54 years. In addition, dyslipidemia, hypertension,

CAD, ipratropium use and >30 annual OPD visits were associated with a higher risk of BPH using multivariate Cox regression analysis.

Figure 1 Cumulative incidence curves of benign prostatic hyperplasia for groups with and without COPD. COPD, chronic obstructive pulmonary disease; BPH, benign prostatic hyperplasia.

Table 2 Cox model measured HRs and 95% CI of BPH associated with COPD and covariates

				HR (95% CI)	
Variable	Event no.	Person-years	IR	Univariate	Multivariate†
COPD					
No	3590	1 39 853	25.7	1.00	1.00
Yes	5690	1 27 246	44.7	1.76 (1.69–1.83)***	1.53 (1.46–1.60)***
Age, years					
40–54	1043	84 598	12.3	1.00	1.00
55–69	3898	1 02 405	38.1	3.14 (2.93–3.36)***	2.76 (2.58–2.96)***
≥70	4339	80 097	54.2	4.63 (4.33–4.95)***	3.84 (3.58–4.12)***
Comorbidity					
DM					
No	7702	2 33 681	33.0	1.00	1.00
Yes	1578	33 419	47.2	1.46 (1.38–1.54)***	0.99 (0.94–1.05)
Dyslipidemia					
No	6774	2 16 531	31.3	1.00	1.00
Yes	2506	50 568	49.6	1.59 (1.52–1.66)***	1.24 (1.18–1.30)***
Hypertension					
No	3868	1 58 724	24.4	1.00	1.00
Yes	5412	1 08 375	49.9	2.09 (2.01–2.18)***	1.25 (1.20–1.31)***
Heart failure					
No	8890	2 60 674	34.1	1.00	1.00
Yes	390	6426	60.7	1.85 (1.67–2.04)***	1.01 (0.91–1.12)
CAD					
No	6341	2 15 607	29.4	1.00	
Yes	2939	51 493	57.1	1.98 (1.89–2.07)***	1.16 (1.10–1.22)***
Medication					
Use of tiotropium					
No	9269	2 66 858	34.7	1.00	1.00
Yes	11	241	45.6	1.30 (0.72 to 2.35)	0.80 (0.44–1.44)
Use of ipratropium					
No	9240	2 66 591	34.7	1.00	1.00
Yes	40	509	78.6	2.35 (1.72–3.20)***	1.48 (1.08–2.02)*
Annual OPD visits					
<30	5103	1 93 353	26.4	1.00	1.00
≥30	4177	73 746	56.6	2.21 (2.12–2.30)***	1.43 (1.37–1.50)***

*p<0.05, ***p<0.001.

†Multivariate Cox proportional hazards regression model including COPD, age (categorical), diabetes mellitus, dyslipidemia, hypertension, heart failure, CAD, tiotropium use, ipratropium use and annual OPD visits (categorical).

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; IR, incidence rate per 1000 person-years; OPD, outpatient department.

The age-stratified results showed that patients with COPD had a significantly higher risk of BPH compared with enrollees without COPD in all age groups. The adjusted HRs of BPH were 1.68 (95% CI 1.46 to 1.94), 1.51 (95% CI 1.41 to 1.62) and 1.36 (95% CI 1.27 to 1.45) for those aged 40–54, 55–69 and over 70 years, respectively. In the comorbidity-stratified analysis, the association between levels of COPD and BPH was similar, except for heart failure (table 3).

DISCUSSION

In this large population-based nationwide cohort study, patients with COPD exhibited a 1.53 times higher risk of BPH compared with enrollees without COPD. Although dyslipidemia, hypertension, ipratropium use and annual OPD visits were associated with a higher risk of BPH, the risk of BPH remained significantly higher in patients with COPD after adjustment for these covariates. According to our review of relevant literature, this is the first cohort

Table 3 Incidence rates and HRs of BPH for the effect of COPD stratified by age and comorbidity

Variable	Non-COPD group				COPD group			Compared with non-COPD group			p for interaction		
	Event no.		Person-years		IR	Event no.		Person-years		IR		HR (95% CI)	
												Crude	Adjusted†
Age, years													
40–54	323	43 202	7.48	720	41 396	17.4				17.4	2.35 (2.06 to 2.68)***	1.68 (1.46–1.94)***	<0.001
55–69	1502	54 092	27.8	2396	48 312	49.6				49.6	1.81 (1.70 to 1.93)***	1.51 (1.41–1.62)***	
≥70	1765	42 559	41.5	2574	37 538	68.6				68.6	1.68 (1.58 to 1.78)***	1.36 (1.27–1.45)***	
Comorbidity													
DM													0.51
No	3015	124 330	24.3	4687	109 351	42.9				42.9	1.79 (1.71 to 1.87)***	1.43 (1.36–1.50)***	
Yes	575	15 524	37.0	1003	17 895	56.1				56.1	1.52 (1.37 to 1.68)***	1.40 (1.25–1.55)***	
Dyslipidemia													0.07
No	2726	118 107	23.1	4048	98 424	41.1				41.1	1.80 (1.72 to 1.89)***	1.45 (1.37–1.52)***	
Yes	864	21 746	39.7	1642	28 822	57.0				57.0	1.44 (1.33 to 1.56)***	1.34 (1.23–1.46)***	
Hypertension													<0.001
No	1641	92 051	17.8	2227	66 674	33.4				33.4	1.89 (1.77 to 2.02)***	1.57 (1.47–1.68)***	
Yes	1949	47 803	40.8	3463	60 572	57.2				57.2	1.41 (1.33 to 1.49)***	1.29 (1.21–1.36)***	
Heart failure													0.008
No	3496	138 087	25.3	5394	122 586	44.0				44.0	1.75 (1.68 to 1.83)***	1.43 (1.37–1.50)***	
Yes	94	1766	53.2	296	4660	63.5				63.5	1.19 (0.94 to 1.50)	1.10 (0.86–1.39)	
CAD													0.005
No	2735	121 169	22.6	3606	94 438	38.2				38.2	1.71 (1.62–1.79)***	1.57 (1.50–1.66)***	
Yes	855	18 684	45.8	2084	32 809	63.5				63.5	1.39 (1.29 to 1.51)***	1.39 (1.28–1.50)***	

***p < 0.001.

†Mutually adjusted for age (continuous), diabetes mellitus, dyslipidemia, hypertension, heart failure, CAD, tiotropium use, ipratropium use and annual OPD visits (continuous). CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; IR, incidence rate per 1000 person-years.

study demonstrating that COPD is associated with increased risk of BPH.

Although the exact underlying mechanisms of the observed relationship between COPD and BPH are unknown, several lines of evidence might offer plausible explanations. First, because inflammation in patients with COPD has been reported in the airway as well as outside the respiratory system,^{5,6} emerging evidence suggests that inflammation also potentially plays a crucial role in BPH development and progression.^{13,20} Higher levels of IL-6 and CRP were found in the serum and induced sputum of patients with COPD.^{14,15,21} Similarly, Schenk *et al* reported that high serum levels of CRP and IL-6 were associated with an increased risk of BPH.¹⁶ Second, Jiang *et al* reported that activation of the hypoxic-inducible factor (HIF)-1 α pathway by the nuclear factor κ B contributed to the development of COPD in animal models,²² whereas Kim *et al* proposed that HIF-1 α mediated BPH under inflammatory conditions in rats,²³ implying that COPD and BPH might share an underlying pathophysiology. Finally, patients with COPD appeared to be more physically inactive than individuals without COPD and reportedly spent substantially less time walking and standing, compared with sedentary healthy older people.^{17,24} A meta-analysis of 11 studies by Parsons *et al* concluded that moderate to vigorous physical activity was associated with decreased risk of BPH or LUTS.¹⁸ Thus, we speculate that physical inactivity among patients with COPD is a contributing factor of increased risk of BPH.

In addition to physical activity, other factors associated with increased risk of BPH include diabetes, dyslipidemia, hypertension and obesity.^{25–27} Therefore, we included diabetes, dyslipidemia and hypertension as comorbidities for adjustment. Our analyses were generally consistent with previous studies,^{25–27} suggesting that dyslipidemia and hypertension were associated with increased risk of BPH. To avoid bias in the study results, we did not further adjust for obesity because diabetes, dyslipidemia and hypertension are already highly associated with obesity.²⁸ On the other hand, Russo *et al* found that in a cross-sectional study in a cohort of patients with LUTS/BPH, moderate-to-severe LUTS was independently associated with Framingham cardiovascular risk score of $\geq 10\%$.²⁹ Therefore, we included CAD as a comorbidity for adjustment. Our results appeared to be consistent with the study by Russo *et al*, suggesting that CAD was significantly associated with increased risk of BPH. The association between cardiovascular diseases and BPH/LUTS merits further investigation.

Patients with >30 annual OPD visits had a 1.43 times higher rate of BPH diagnosis compared with enrollees with fewer than 30 annual OPD visits. To minimise surveillance bias, we used annual OPD visits as a covariate for adjustment. The data revealed that COPD is a predisposing factor independent of annual OPD visits.

Cigarette smoking is a strong predisposing factor for COPD development. By contrast, previous studies have suggested that smokers may be less likely to develop BPH

than non-smokers. For example, Kupeli *et al* reported that the mean prostate volume was lower in smokers than in non-smokers,³⁰ and Matzkin *et al* observed that prostate size did not differ between current smokers, ex-smokers and never-smokers.³¹ Moreover, a recent meta-analysis combining eight observational studies indicated there is no significant association between smoking and BPH risk either for ex-smokers or current smokers.³² Although the NHIRD does not contain information regarding smoking habits of enrollees, a recent study by Cheng *et al* indicated that approximately 82.9% of patients with COPD are ever-smokers in Taiwan.³³ A public health report released by the Ministry of Health and Welfare of Taiwan indicated that the ratio of smokers in the male population of Taiwan was 44.3% in individuals aged 41–45 years, and 14.9% in individuals aged over 66 years.³⁴ We reasoned that the data from Cheng *et al*³³ could be attributed to the ratio of smokers in the COPD group; and the data from Ministry of Health and Welfare of Taiwan³⁴ could be attributed to the ratio of smoker in the non-COPD group in our study. Altogether, we speculate that although the ratio of smokers is higher in the COPD group than in the non-COPD group, the higher risk of BPH in patients with COPD might not be confounded by mechanisms related to cigarette smoking.

The stratified analysis demonstrated that the incidence of BPH substantially increased with age in both groups. However, the HRs of BPH decreased with an increase in age. This decrease may be because the comorbidities of COPD increased with age, thus attenuating the influence of COPD on BPH development when we adjusted for comorbidities.

Anticholinergic agents (ipratropium and tiotropium) are extensively used for maintenance treatment in patients with COPD. Previous studies have suggested that anticholinergic agents are associated with acute urinary retention, which implies that these medications might increase the risk of BPH.^{35,36} In our analysis, long-term tiotropium use did not alter the risk of BPH, which was consistent with the study by Miyazaki *et al*.³⁷ By contrast, ipratropium was associated with increased BPH risk. In our study, none of the tiotropium was administered using a nebuliser, whereas some ipratropium was administered using a nebuliser. The association between ipratropium use and BPH risk may be partly explained by ipratropium being administered using a nebuliser, which exerts more systemic effects compared with other forms of anticholinergic agents, such as a dry powder inhaler or a metered dose inhaler. A nested case-control study by Afonso *et al* suggests that acute urinary retention is associated with the use of inhaled anticholinergic agent, particularly that administered using a nebuliser.³⁶ However, in the present observational study, which employed encrypted secondary data, we were unable to access details of each enrollee to examine the adherence of prescribed medications, which may potentially bias our interpretations.

The strength of our study is that we retrieved data from the NHIRD, which is highly representative of the general

population. Nevertheless, several limitations of our study should be addressed. First, a lack of detailed patient information involving cigarette smoking habits, body mass index, dietary preference and family history of systemic disease in the NHIRD may have yielded biased study results because these may be risk factors or comorbidities of BPH. Second, each diagnosis was based on ICD-9-CM codes obtained from administrative data. Detailed information regarding clinical variables, such as lung function tests, image results, serum prostate-specific antigen and prostate volume were unavailable. Therefore, determining whether more severe COPD further increased the risk of BPH was challenging. Finally, despite our meticulous study design, unknown confounding factors might remain, leading to bias in our study results. However, we believe that the relationship between COPD and BPH demonstrated in the present study is highly reliable because of the database validity, a large sample size and long follow-up periods.

In summary, our study suggests that all patients with COPD aged 40 years and over have a higher future risk of BPH. We suggest that clinicians should be cautious about the increased risk of BPH in patients with COPD. Future research is warranted to validate our results and elucidate the pathophysiology of these two diseases.

Author affiliations

¹Department of Public Health, China Medical University, Taichung, Taiwan

²Division of Respiratory Therapy, Asia University Hospital, Asia University, Taichung, Taiwan

³Department of Respiratory Therapy, China Medical University, Taichung, Taiwan

⁴Division of Chest Medicine, Department of Internal Medicine, Asia University Hospital, Taichung, Taiwan

⁵Department of Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan

⁶Institute of Molecular Biology, College of Life Sciences, National Chung Hsing University, Taichung, Taiwan

⁷Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan

⁸College of Medicine, China Medical University, Taichung, Taiwan

⁹Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

¹⁰Department of Respiratory Therapy, China Medical University Hospital, China Medical University, Taichung, Taiwan

¹¹Department of Health Care Administration, Asia University, Taichung, Taiwan

Contributors Y-HP, C-WH, W-CL and W-CH were involved in conception and design, T-NW and H-JC were involved in administrative support, Y-HP, M-CY, Y-MH and W-CH were involved in collection and assembly of data. All authors involved in manuscript writing and final approval of the manuscript.

Funding This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing interests None declared.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed

information available and are satisfied that the information backs up the case the authors are making.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. World Health Organization. The top 10 causes of death. <http://www.who.int/mediacentre/factsheets/fs310/en/> (accessed 12 Dec 2016).
2. Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. *Respir Investig* 2015;53:249–58.
3. Liao WC, Lin CL, Chang SN, et al. The association between chronic obstructive pulmonary disease and dementia: a population-based retrospective cohort study. *Eur J Neurol* 2015;22:334–40.
4. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2014;9:871–88.
5. Agustí A, Soriano JB. COPD as a systemic disease. *COPD* 2008;5:133–8.
6. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? *Lancet* 2007;370:797–9.
7. Garraway WM, Lee RJ, Collins GN. High prevalence of benign prostatic hypertrophy in the community. *The Lancet* 1991;338:469–71.
8. Thorpe A, Neal D. Benign prostatic hyperplasia. *Lancet* 2003;361:1359–67.
9. De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. *Eur Urol* 2012;61:560–70.
10. Parsons JK, Sarma AV, McVary K, et al. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. *J Urol* 2013;189:S102–S106.
11. Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. *Phys Sportsmed* 2009;37:75–83.
12. Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). *J Thorac Dis* 2014;6:1532–47.
13. Bostanci Y, Kazzazi A, Momtahan S, et al. Correlation between benign prostatic Hyperplasia and inflammation. *Curr Opin Urol* 2013;23:5–10.
14. Grubek-Jaworska H, Papińska M, Hermanowicz-Salamon J, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. *Respiration* 2012;84:101–7.
15. Karadag F, Kirdar S, Karul AB, et al. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. *Eur J Intern Med* 2008;19:104–8.
16. Schenk JM, Kristal AR, Neuhauser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic Hyperplasia: results from the prostate Cancer prevention trial. *Am J Epidemiol* 2010;171:571–82.
17. Spruit MA, Pitta F, McAuley E, et al. Pulmonary Rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015;192:924–33.
18. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. *Eur Urol* 2008;53:1228–35.
19. National Health Insurance Research Database. Website http://nhird.nhi.gov.tw/en/Data_Subsets.html (accessed 9 Apr 2017).
20. Donnell RF. Benign prostate Hyperplasia: a review of the year's progress from bench to clinic. *Curr Opin Urol* 2011;21:22–6.
21. Zhang Y, Bunjhoo H, Xiong W, et al. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *J Int Med Res* 2012;40:1629–35.
22. Jiang H, Zhu Y, Xu H, et al. Activation of hypoxia-inducible factor-1alpha via nuclear factor-kappa B in rats with chronic obstructive pulmonary disease. *Acta Biochim Biophys Sin* 2010;42:483–8.

23. Kim HJ, Park JW, Cho YS, *et al.* Pathogenic role of HIF-1 α in prostate hyperplasia in the presence of chronic inflammation. *Biochim Biophys Acta* 2013;1832:183–94.
24. Pitta F, Troosters T, Spruit MA, *et al.* Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;171:972–7.
25. Hwang EC, Kim SO, Nam DH, *et al.* Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume. *LUTS: Lower Urinary Tract Symptoms* 2015;7:32–6.
26. Chu KF, Rotker K, Ellsworth P. The impact of obesity on benign and malignant urologic conditions. *Postgrad Med* 2013;125:53–69.
27. Parsons JK, factors L. Lifestyle factors, benign prostatic Hyperplasia, and lower urinary tract symptoms. *Curr Opin Urol* 2011;21:1–4.
28. Kyrou I, Randeva HS, Weickert MO, *et al.* Clinical Problems Caused by Obesity. In: De Groot LJ, Beck-Peccoz P, Chrousos G, eds. *Endotext*. South Dartmouth (MA), 2000.
29. Russo GI, Castelli T, Privitera S, *et al.* Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. *BJU Int* 2015;116:791–6.
30. Küpeli B, Soygür T, Aydos K, *et al.* The role of cigarette smoking in prostatic enlargement. *Br J Urol* 1997;80:201–4.
31. Matzkin H, Cytron S, Simon D. Is there an association between cigarette smoking and gland size in benign prostatic Hyperplasia? *Prostate* 1996;29:42–5.
32. Xu H, Fu S, Chen Y, *et al.* Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies. *Medicine* 2016;95:e4565.
33. Cheng SL, Chan MC, Wang CC, *et al.* COPD in Taiwan: a National Epidemiology Survey. *Int J Chron Obstruct Pulmon Dis* 2015;10:2459–67.
34. Adult Smoking Behavior Surveillance System, Ministry of Health and Welfare of Taiwan, Website: <http://tobacco.hpa.gov.tw/Show.aspx?MenuId=581> Accessed Dec 12, 2016,;:–.
35. Loke YK, Singh S. Risk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review. *Ther Adv Drug Saf* 2013;4:19–26.
36. Afonso AS, Verhamme KM, Stricker BH, *et al.* Inhaled anticholinergic drugs and risk of acute urinary retention. *BJU Int* 2011;107:1265–72.
37. Miyazaki H, Suda T, Otsuka A, *et al.* Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia. *Pulm Pharmacol Ther* 2008;21:879–83.